Displaying drugs 6976 - 7000 of 8090 in total
Acumapimod
Acumapimod is under investigation in clinical trial NCT02926326 (The Effect of Azithromycin on BCT197 Exposure in Healthy Male Volunteers).
Investigational
Matched Description: … Acumapimod is under investigation in clinical trial NCT02926326 (The Effect of Azithromycin on BCT197 …
PF-05105679
PF-05105679 is under investigation in clinical trial NCT01393652 (Single Dose, Dose Escalation Healthy Volunteers Study Of PF-05105679).
Investigational
Matched Description: … investigation in clinical trial NCT01393652 (Single Dose, Dose Escalation Healthy Volunteers Study Of …
Pabinafusp alfa
Pabinafusp alfa is under investigation in clinical trial NCT03568175 (A Study of JR-141 in Patients With Mucopolysaccharidosis II).
Investigational
Matched Description: … Pabinafusp alfa is under investigation in clinical trial NCT03568175 (A Study of JR-141 in Patients With …
JBPOS0101
JBPOS0101 is under investigation in clinical trial NCT03976076 (A Study of Orally Administered JBPOS0101 in Refractory Infantile Spasms Patients).
Investigational
Matched Description: … JBPOS0101 is under investigation in clinical trial NCT03976076 (A Study of Orally Administered JBPOS0101 …
Farudodstat
Farudodstat (ASLAN003) is under investigation in clinical trial NCT03451084 (A Dose Optimisation Study of ASLAN003 in Acute Myeloid Leukemia).
Investigational
Matched Description: … Farudodstat (ASLAN003) is under investigation in clinical trial NCT03451084 (A Dose Optimisation Study of …
ARRY-502
ARRY-502 is under investigation in clinical trial NCT01561690 (A Study of ARRY-502 in Patients With Persistent Asthma).
Investigational
Matched Description: … ARRY-502 is under investigation in clinical trial NCT01561690 (A Study of ARRY-502 in Patients With Persistent …
Artemisone
Artemisone is under investigation in clinical trial NCT00936767 (Artemisone for the Treatment of Uncomplicated Falciparum Malaria in Western Cambodia).
Investigational
Matched Description: … Artemisone is under investigation in clinical trial NCT00936767 (Artemisone for the Treatment of Uncomplicated …
Lapaquistat
Lapaquistat is under investigation in clinical trial NCT00256178 (Efficacy of Lapaquistat Acetate and Simvastatin in Subjects With Primary Dyslipidemia.).
Investigational
Matched Description: … Lapaquistat is under investigation in clinical trial NCT00256178 (Efficacy of Lapaquistat Acetate and …
Nidufexor
Nidufexor is under investigation in clinical trial NCT03804879 (Safety, Tolerability and Efficacy of LMB763 in Patients With Diabetic Nephropathy).
Investigational
Matched Description: … Nidufexor is under investigation in clinical trial NCT03804879 (Safety, Tolerability and Efficacy of …
TAK-653
TAK-653 is under investigation in clinical trial NCT03312894 (Efficacy and Safety of TAK-653 in Treatment-resistant Depression).
Investigational
Matched Description: … TAK-653 is under investigation in clinical trial NCT03312894 (Efficacy and Safety of TAK-653 in Treatment-resistant …
Coprelotamab
Coprelotamab is under investigation in clinical trial NCT04170595 (Clinical Study of Recombinant Anti-her2 Humanized Monoclonal Antibody for Injection).
Investigational
Matched Description: … Coprelotamab is under investigation in clinical trial NCT04170595 (Clinical Study of Recombinant Anti-her2 …
Zotatifin
Zotatifin is under investigation in clinical trial NCT04092673 (Study of Eft226 in Subjects With Selected Advanced Solid Tumor Malignancies).
Investigational
Matched Description: … Zotatifin is under investigation in clinical trial NCT04092673 (Study of Eft226 in Subjects With Selected …
Uliledlimab
Uliledlimab is under investigation in clinical trial NCT04322006 (A Phase I/II Study of TJ004309 for Advanced Solid Tumor).
Investigational
Matched Description: … Uliledlimab is under investigation in clinical trial NCT04322006 (A Phase I/II Study of TJ004309 for …
Lirentelimab
Lirentelimab is under investigation in clinical trial NCT04856891 (A Study of Lirentelimab (AK002) in Patients With Active Eosinophilic Duodenitis).
Investigational
Matched Description: … Lirentelimab is under investigation in clinical trial NCT04856891 (A Study of Lirentelimab (AK002) in …
SRP-6004
A recombinant AAVrh74 gene therapy expressing the dysferlin transgene under control of a muscle-specific promoter (rAAVrh74.MHCK7.DYSF.DV).
Investigational
Matched Description: … A recombinant AAVrh74 gene therapy expressing the dysferlin transgene under control of a muscle-specific …
JNJ-17216498
JNJ-17216498 is a histamine receptor H3 antagonist developed by Johnson and Johnson for the treatment of narcolepsy.
Investigational
Matched Description: … JNJ-17216498 is a histamine receptor H3 antagonist developed by Johnson and Johnson for the treatment of …
ORC-13661
ORC-13661 is under investigation in clinical trial NCT05730283 (Prevention of Ototoxicity in NTM Patients Treated With IV Amikacin).
Investigational
Matched Description: … ORC-13661 is under investigation in clinical trial NCT05730283 (Prevention of Ototoxicity in NTM Patients …
Piclamilast
Piclamilast (RP-73,401), is a selective PDE4 inhibitor comparable to other PDE4 inhibitors for its anti-inflammatory effects. It has been investigated for its applications to the treatment of conditions such as chronic obstructive pulmonary disease, bronchopulmonary dysplasia and asthma. The structure for piclamilast was first elucidated in a 1995 European patent...
Experimental
Matched Description: … It has been investigated for its applications to the treatment of conditions such as chronic obstructive ... first elucidated in a 1995 European patent application and exhibits the structural functionalities of …
Rindopepimut
Rindopepimut (CDX-110) is an injectable peptide cancer vaccine which targets a mutant protein called EGFRvIII present in about 25% to 30% of glioblastoma cases. The vaccine consists of the EGFRv3-specific peptide (a 13-amino acid mutant vIII epitope) conjugated to the non-specific immunomodulator keyhole limpet hemocyanin (KLH). The US FDA granted...
Investigational
Matched Description: … The vaccine consists of the EGFRv3-specific peptide (a 13-amino acid mutant vIII epitope) conjugated ... injectable peptide cancer vaccine which targets a mutant protein called EGFRvIII present in about 25% to 30% of …
Velafermin
Velafermin was a novel investigational protein therapeutic, also known as fibroblast growth factor-20 (FGF-20), which promotes both epithelial and mesenchymal cell proliferation in vitro and has demonstrated activity in multiple animal models. Velafermin was investigated as a potential therapy for the prevention and treatment of oral mucositis by fostering the...
Investigational
Matched Description: … by fostering the regeneration and repair of the cells lining the gastrointestinal tract. ... Velafermin was investigated as a potential therapy for the prevention and treatment of oral mucositis …
Valopicitabine
The 3-O-valine ester prodrug of the nucleoside analog 2'-C-methylcytidine with anti-hepatitis C virus (HCV) activity. Upon administration, valopicitabine is converted into 2'-C-methylcytidine; upon phosphorylation into its 5-triphosphate form, this metabolite inhibits viral RNA chain elongation and viral RNA-dependent RNA polymerase activity. This blocks viral production of HCV RNA and thus...
Experimental
Matched Description: … This blocks viral production of HCV RNA and thus viral replication. [from NCI] ... The 3-O-valine ester prodrug of the nucleoside analog 2'-C-methylcytidine with anti-hepatitis C virus …
Erythroxylum catuaba bark
"Catuaba" is a general term for a medicinal infusion created by the bark of plants belonging to the Erythroxylum genus, though this name is also applied to infusions of plants belonging to other genera. The infusion is thought to carry stimulant and aphrodisiac effects, and catuaba made specifically with Trichilia...
Experimental
Matched Description: … "Catuaba" is a general term for a medicinal infusion created by the bark of plants belonging to the _ ... Erythroxylum_ genus, though this name is also applied to infusions of plants belonging to other genera …
CVnCoV Vaccine
The CVnCov Vaccine (or CV07050101) is in development by CureVac AG. The vaccine uses mRNA technology to create a protein associated with SARS-CoV2, and upon administration and replication, to initiate subsequent immune responses in the body. As of June 2020, the company received regulatory approval from German and Belgian Authorities...
Investigational
Matched Description: … Phase 1 clinical trials of this vaccine (NCT04449276). ... As of June 2020, the company received regulatory approval from German and Belgian Authorities to commence …
Fenretinide
A synthetic retinoid that is used orally as a chemopreventive against prostate cancer and in women at risk of developing contralateral breast cancer. It is also effective as an antineoplastic agent.
Investigational
Matched Description: … synthetic retinoid that is used orally as a chemopreventive against prostate cancer and in women at risk of …
VIR201
is an experimental therapeutic vaccine currently in clinical trial. The aim of therapeutic vaccines is to augment the body's immune response to HIV and to delay or prevent progression to AIDS.
Investigational
Matched Description: … The aim of therapeutic vaccines is to augment the body's immune response to HIV and to delay or prevent …
Displaying drugs 6976 - 7000 of 8090 in total